Acute Respiratory Distress Syndrome News and Research

RSS

Melatonin as a safe and potentially life-saving treatment for COVID-19

A new study discusses the possible role of melatonin, an antioxidant and anti-inflammatory agent, in treating COVID-19.

24 Feb 2022

SARS-CoV-2 viroporins mediate cytokine storm via mitochondrial permeability transition pore

Researchers demonstrated that the SARS-CoV-2 viroporins precipitate cytokine storm via the alteration of mitochondrial physiology in severe COVID-19.

24 Feb 2022

Pre-existing B-cell immunity against SARS-CoV-2 not detected in pre-pandemic samples

A recent study investigates samples solated from unexposed individuals pre-pandemic to determine the presence of pre-existing SARS-CoV-2 B-cell immunity.

22 Feb 2022

Mechanisms of IL-6 expression in peripheral monocyte-derived macrophages infected with SARS-CoV-2

Researchers examined the detailed mechanisms of ‘cytokine storm’ that induces ARDS, often resulting in the death of severely ill COVID-19 patients.

21 Feb 2022

Study suggests tea polyphenols may modulate COVID-19 via intestinal microbiota

A new study discusses the state of current knowledge about the potential use of tea polyphenols in the prevention and treatment of COVID-19.

16 Feb 2022

Incomplete repair of the damaged lung may contribute to death from COVID-19 and non-COVID ARDS

Investigators studying lung cells have discovered that the normal repair process that occurs after lung disease or injury appears to be incomplete but still ongoing in patients who died of COVID-19 and non-COVID acute respiratory distress syndrome (ARDS).

15 Feb 2022

Cardiovascular markers for predicting clinical outcomes in SARS-CoV-2 infection

In a recent study posted to the medRxiv* preprint server, an interdisciplinary team of researchers from Toronto, Canada, characterized the markers of endothelial function and developed micro ribonucleic acid (miRNA) expression atlas in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive and -negative patients admitted to the intensive care unit (ICU).

15 Feb 2022

How SARS-CoV-2 infection progresses throughout the respiratory system

Researchers discuss the progression of SARS-CoV-2 infection throughout the respiratory epithelium.

9 Feb 2022

FDA-approved drug prevents the immune system from producing neutrophil extracellular traps

A team of scientists led by Cold Spring Harbor Laboratory (CSHL) have discovered that disulfiram, an FDA-approved drug, prevents the immune system from producing toxic webs known as neutrophil extracellular traps (NETs).

8 Feb 2022

Colchicine holds promise to reduce the risk of severe COVID-19

A recent article, published in Rheumatology and Therapy, reviews the potent evidence of colchicine against the SARS-CoV-2 infection.

7 Feb 2022

Dizziness is a common symptom of COVID-19

New research published in Internal and Emergency Medicine discusses the relationship between SARS-CoV-2 infection and dizziness.

6 Feb 2022

Study reveals peripheral blood biomarkers able to predict COVID-19 clinical outcomes in ICU admission

A new study involved the development of an immunological biomarker screen that upon ICU admission can predict the length of ICU stay or death.

3 Feb 2022

Study identifies drugs that could help combat mortality in patients with COVID-19

Inflammation is a defense mechanism of the body to fight pathogens. However, when it is widespread and excessive, it can aggravate the pathology and even cause death.

31 Jan 2022

γ’ fibrinogen as a disease progression marker for COVID-19

Levels of the inflammatory biomarker gamma prime fibrinogen (γ' Fbg) varies according to severity in COVID-19 patients.

28 Jan 2022

Intranasal interferon-λ treatment protects mice against SARS-CoV-2 Beta and Omicron variants

Researchers investigate the possible efficacy of IFN-λ in the context of SARS-CoV-2 infection in mice.

28 Jan 2022

Early-stage alveolar epithelial cell necrosis linked to COVID-19-induced acute respiratory distress syndrome

A new study analyzed whether alveolar epithelial cell necrosis at an early stage SARS-CoV-2 infection and subsequent releases of damage-associated molecular patterns could aggravate COVID-19-associated acute respiratory distress syndrome.

27 Jan 2022

Cedars-Sinai experts conduct a national analysis on COVID-19 lung transplants

The analysis of more than 3,000 lung transplants in the U.S. between Aug. 1, 2020, and Sept. 30, 2021, showed that during the pandemic, 7% of the nation's lung transplants were performed to treat severe, irreversible lung damage caused by COVID-19. More than half of these patients needed ventilators or extracorporeal membrane oxygenation, or ECMO, before their transplant.